Michael C Lowe
Overview
Explore the profile of Michael C Lowe including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
42
Citations
428
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
2.
Sebastian N, Stokes W, Behera M, Jiang R, Gutman D, Huang Z, et al.
Oncologist
. 2024 Sep;
30(2).
PMID: 39321212
Background: Preclinical data suggest antifungal azole derivatives have antitumor efficacy that may modulate response to immune checkpoint inhibitors (ICIs). We aimed to evaluate the association of azole drugs with overall...
3.
Zager J, Orloff M, Ferrucci P, Choi J, Eschelman D, Glazer E, et al.
Ann Surg Oncol
. 2024 Jul;
31(12):8262-8263.
PMID: 39026142
No abstract available.
4.
Zager J, Orloff M, Ferrucci P, Choi J, Eschelman D, Glazer E, et al.
Ann Surg Oncol
. 2024 May;
31(8):5340-5351.
PMID: 38704501
Background: Uveal melanoma (UM) has a poor prognosis once liver metastases occur. The melphalan/Hepatic Delivery System (melphalan/HDS) is a drug/device combination used for liver-directed treatment of metastatic UM (mUM) patients....
5.
Patel J, Woo Y, Draper A, Jansen C, Carlisle J, Innominato P, et al.
J Immunother Cancer
. 2024 Mar;
12(3).
PMID: 38531662
Background: Recent studies have demonstrated that earlier time-of-day infusion of immune checkpoint inhibitors (ICIs) is associated with longer progression-free survival (PFS) and overall survival (OS) among patients with metastatic melanoma...
6.
Shen Y, Connolly E, Aiello M, Zhou C, Chappa P, Song H, et al.
Res Sq
. 2024 Mar;
PMID: 38496632
Radiotherapy (RT) and anti-PD-L1 synergize to enhance local and distant (abscopal) tumor control. However, clinical results in humans have been variable. With the goal of improving clinical outcomes, we investigated...
7.
Bennion K, Tariq M, Wyatt M, Duneton C, Baecher K, Paulos C, et al.
Sci Transl Med
. 2023 Aug;
15(710):eadd1868.
PMID: 37611081
Checkpoint inhibition using Fc-containing monoclonal antibodies has emerged as a powerful therapeutic approach to augment antitumor immunity. We recently showed that FcγRIIB, the only inhibitory IgG-Fc receptor, is expressed on...
8.
Mallarino-Haeger C, Pino M, Viox E, Pagliuzza A, King C, Nguyen K, et al.
J Virol
. 2023 Mar;
97(4):e0167022.
PMID: 36971588
Elucidating the mechanisms underlying the persistence and location of the HIV reservoir is critical for developing cure interventions. While it has been shown that levels of T-cell activation and the...
9.
Patel S, Othus M, Chen Y, Wright Jr G, Yost K, Hyngstrom J, et al.
N Engl J Med
. 2023 Mar;
388(9):813-823.
PMID: 36856617
Background: Whether pembrolizumab given both before surgery (neoadjuvant therapy) and after surgery (adjuvant therapy), as compared with pembrolizumab given as adjuvant therapy alone, would increase event-free survival among patients with...
10.
Sebastian N, Stokes W, Behera M, Jiang R, Gutman D, Huang Z, et al.
Clin Lung Cancer
. 2023 Feb;
24(3):287-294.
PMID: 36804711
Background: Immune checkpoint inhibitors (ICI) are commonly used in the management of patients with advanced non-small cell lung cancer (NSCLC), but response is suboptimal. Preclinical data suggest ICI efficacy may...